Merus Labs announces exclusive licensing agreement with Innocoll Pharmaceuticals
The three products are indicated for the management of painful wounds including diabetic ulcers, venous ulcers, pressure ulcers, full and partial thickness wounds, 1st and 2nd degree burns and dehisced surgical wounds.
The worldwide advanced wound care market is estimated to be worth $5.5bn in 2010. This market is expected to grow by approximately 5.7% to 6% out to 2013.
"We are very pleased to announce this strategic partnership with Innocoll to launch such unique products in Canada. Innocoll is an innovator and world leader in the area of drug delivery and advanced wound care. This partnership with Innocoll will greatly enhance Merus' pipeline of, ready to launch, innovative products in the Canadian market place, significantly enhancing patient care." said Ahmad Doroudian, president & CEO of Merus.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.